Papers published by members our Cancer Informatics Research Group
2026
- Atter M, Bullen A, Cresswell K, Hall PS. Cost-Effectiveness of Electronic Patient-Reported Outcome Measure Interventions in Cancer: A Systematic Review and Parameter Extraction for Economic Modelling (Preprint). 2026.
- Abravan A, Fornacon-Wood I, Kingston R, Topping D, Price G. Environmental determinants of cancer outcomes: a scoping review. Radiotherapy and Oncology. 2026;217:111408–111408.
- Ellis L, Eversfield C, Gray E, Hall P, Hiom S, Jones DA, Lee LY, McPhail S, Spencer K, Halloran C. Modelled impact of a multi-cancer early detection screening programme on cancer treatment in England. British Journal of Cancer. 2026.
- Nailon WH, Noble DJ, Harrison E, Yang Z, Elliot S, MacNair A, Beckett G, Hallam A, Sheikh A, Mills N, others. Protocol for the PROSECCA study: a new approach for predicting radiotherapy outcome using artificial intelligence and electronic population-based healthcare data. BMJ open. 2026;16(2):e104408.
- Angrisani A, Kirova Y, Abravan A, Becherini C, Benavente S, Castelo-Branco LS, Chalmers AJ, Christ SM, Deutsch E, Filippi AR, Hendriks LEL, Zolcsók Z, Illidge T, Rimner A, Herrera F, Ruysscher DD. Radiotherapy for more efficacious novel anticancer drugs: a position paper from the European Society for Radiotherapy and Oncology (ESTRO) focus group on novel systemic therapies and radiotherapy. Universität Zürich, ZORA. 2026.
2025
- Stein RC, Marshall A, Makris A, Hughes‐Davies L, Macpherson I, Hopkins A, Cameron DA, Canney P, Earl H, Rea DW, Bayani J, Hall P, McCabe CJ, Donovan J, Harmer V, Pinder S, Rooshenas L, Morgan A, Bartlett JMS, Dunn J. 190O Clinical outcomes in the OPTIMA prelim (Optimal Personalised Treatment of early breast cancer using Multi-Parameter Analysis) feasibility study. ESMO Open. 2025;10:104744–104744.
- Davie A, Traoré S, Badreldin W, Torstensson A, Cakar E, McCullough AC, Tempelaar S, Fenwick E, Hall PS. A cost-effectiveness analysis of abemaciclib in combination with adjuvant endocrine therapy for HR+, HER2–, node-positive, high-risk early breast cancer. Advances in Therapy. 2025;42(6):2767–2781.
- Mukhtar RA, Gottipati S, Yau C, López‐Tarruella S, Earl H, Hayward L, Hiller L, Osdoit M, Noordaa MVD, Croze DD, Hamy AS, Laé M, Reyal F, Sonke GS, Steenbruggen TG, Seijen MV, Wesseling J, Martín M, Monte-Millán MAD, Boughey JC, et al. A pooled analysis evaluating prognostic significance of Residual Cancer Burden in invasive lobular breast cancer. npj Breast Cancer. 2025;11(1):14–14.
- Walsh T, Emerson LM, Singleton J, Locherty R, Hope D, Cholbi S, Giddings AEB, Macdonald A, Lone N, Docherty AB, Mead G, Stanworth S, Drakesmith A, Roy NM, Hall P, Neilson A, Pollock R, Rodríguez A, Norrie J, Weir CJ, et al. Anaemia management with red blood cell transfusion to improve post-intensive care disability: Protocol for the ABC post-ICU randomised controlled trial. Journal of the Intensive Care Society. 2025;27(1):98–106.
- Dunn JA, Donnelly P, Elbeltagi N, Marshall A, Hopkins A, Thompson AM, Audisio R, Pinder SE, Cameron DA, Hartup S, others. Annual versus less frequent mammographic surveillance in people with breast cancer aged 50 years and older in the UK (Mammo-50): a multicentre, randomised, phase 3, non-inferiority trial. The Lancet. 2025;405(10476):396–407.
- Cocco P, Bojke C, Hulme C, Hall PS, Hopkins A, Marshall A, Dunn JA, Meads D, Shinkins B. Annual versus less frequent mammographic surveillance in people with breast cancer aged 50 years and older in the UK (Mammo-50): cost-effectiveness and budget impact analysis: Epidemiology. British Journal of Cancer. 2025:1–7.
- Loganath K, Lee KK, Oikonomidou O, Hall P, Mills NL, Joshi S, Singh T, McGillivray T, Semple S, Lang NN, Dweck MR, Henriksen P. Anthracycline Dose, Myocardial Injury, and Change in Left Ventricular Function in the Cardiac CARE Trial. JACC CardioOncology. 2025;7(6):725–735.
- Loganath K, Lee KK, Oikonomidou O, Hall P, Mills NL, Joshi S, Singh T, McGillivray T, Semple S, Lang NN, others. Anthracycline dose, myocardial injury, and change in left ventricular function in the Cardiac CARE trial. Cardio Oncology. 2025;7(6):725–735.
- Cottu P, Cheeseman S, Hall P, Wöckel A, Scholz CW, Bria E, Orlandi A, Ribelles N, Vallet MV, Niklas N, others. Attrition between lines of therapy and real-world outcomes of patients with HER2-positive metastatic breast cancer in Europe: a cohort study leveraging electronic medical records. Breast cancer research and treatment. 2025;209(2):419–430.
- Sears A, Wild SH, Mesa‐Eguiagaray I, Hall P, Figueroa JD. Breast cancer survival and mortality among women with type 2 diabetes: a retrospective cohort study. Scientific Reports. 2025;15(1):26144–26144.
- Sears AJ, Wild SH, Mesa-Eguiagaray I, Hall PS, Figueroa JD. Breast cancer survival and mortality among women with type 2 diabetes: a retrospective cohort study. Scientific Reports. 2025;15(1):26144.
- Mesa‐Eguiagaray I, Wild SH, Williams L, Jin K, Bird SM, Brewster D, Hall P, Figueroa JD. Breast cancer-specific survival by molecular subtype in different age groups of women in Scotland. Breast Cancer Research. 2025;27(1):59–59.
- Mesa-Eguiagaray I, Wild SH, Williams LJ, Jin K, Bird SM, Brewster DH, Hall PS, Figueroa JD. Breast cancer-specific survival by molecular subtype in different age groups of women in Scotland. Breast Cancer Research. 2025;27(1):59.
- Hatton N, Baxter M, Lewis S, Hall P, Spencer K. KERMIT: Performance indicators in electronic patient reported outcome measures: a modified Delphi. Journal of Patient-Reported Outcomes. 2025;9(1):81–81.
- Hatton NL, Baxter M, Lewis S, Hall PS, Spencer K. KERMIT: Performance indicators in electronic patient reported outcome measures: a modified Delphi. Journal of Patient-Reported Outcomes. 2025;9(1):81.
- Haining K, Lemmon E, Hall P, Lone NI. Long-term costs associated with healthcare use of people with cancer in Scotland: K. Haining et al. The European Journal of Health Economics. 2025:1–15.
- Salman RAS, Kitchen N, Forsyth L, Ganesan V, Hall P, Harkness K, Hutchinson PJ, Lewis S, Radatz M, Turner C, Wade J, White D, White P. Medical management and intervention (using neurosurgical resection or stereotactic radiosurgery) versus medical management alone for symptomatic brain cavernoma: the CARE pilot RCT. Health Technology Assessment. 2025;29(38):1–24.
- Salman RAS, Kitchen N, Forsyth L, Ganesan V, Hall PS, Harkness K, Hutchinson PJ, Lewis SC, Radatz MW, Turner C, others. Medical management and intervention (using neurosurgical resection or stereotactic radiosurgery) versus medical management alone for symptomatic brain cavernoma: the CARE pilot RCT. Health Technology Assessment (Winchester, England). 2025;29(38):1.
- Atter MJ, Hall P, Evans RA, Norrie J, Cohen J, Williams B, Chaudhuri N, Bajwah S, Higginson I, Pearson M, others. Morphine for chronic breathlessness (MABEL) in the UK: a health economic evaluation of a multisite, parallel-group, dose titration, double-blind, randomised, placebo-controlled trial. BMJ open. 2025;15(11):e102124.
- Johnson MJ, Williams B, Keerie C, Tuck S, Hart SP, Bajwah S, Chaudhuri N, Pearson M, Cohen J, Evans RA, Currow DC, Higginson IJ, Hall P, Atter M, Norrie J, Fallon M, Hart SP, Barrett SA, Bayes H, Stewart G, et al. Morphine for chronic breathlessness (MABEL) in the UK: a multi-site, parallel-group, dose titration, double-blind, randomised, placebo-controlled trial. The Lancet Respiratory Medicine. 2025;13(11):967–977.
- Phillips I, McDougall C, Walton A, Stares M, Hall P, Grecian R, O’Brien F, Mencnarowski J, MacCormick F, McLean G, Higgins SL, McMillan D, Reid C, Allan L, Lim BH, Barrie C. Multidisciplinary Prehabilitation Reduces Hospitalization Time and Suggests Improved Survival in Patients with Radiologically Diagnosed Lung Cancer. Cancers. 2025;17(20):3329–3329.
- Phillips I, McDougall C, Walton A, Stares M, Hall P, Grecian R, O’Brien F, Mencnarowski J, MacCormick F, McLean G, others. Multidisciplinary prehabilitation reduces hospitalization time and suggests improved survival in patients with radiologically diagnosed lung cancer. Cancers. 2025;17(20):3329.
- Tao Y, Lang CC, Petty R, Hall P, Baxter M. N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP)—A Prognostic Biomarker in Older and/or Frail Adults with Advanced Gastroesophageal Cancer: A Post Hoc Analysis of the GO2 Clinical Trial. Cancers. 2025;17(4):601–601.
- Lucocq J, Erskine E, Hall P. The risk of contralateral breast cancer during long-term follow-up after breast conserving surgery to inform tailored surveillance protocols. European Journal of Surgical Oncology. 2025;51:109944–109944.
2024
- Coakley M, Villacampa G, Sritharan P, Swift C, Dunne K, Kilburn L, Goddard K, Pipinikas C, Rojas P, Emmett W, Hall P, Harper-Wynne C, Hickish T, Macpherson I, Okines A, Wardley A, Wheatley D, Waters S, Palmieri C, Winter M, et al. Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast Cancer. Clin. Cancer Res. 2024;30(4):895–903.
- Phillips I, Deans M, Walton A, Vallet MV, Mencnarowksi J, McMillan D, Peacock C, Hall P, O’Brien F, Stares M, others. Early prehabilitation reduces admissions and time in hospital in patients with newly diagnosed lung cancer. BMJ Supportive & Palliative Care. 2024;15(1):125–129.
- Peters AL, Hall PS, Jordan LB, Soh FY, Hannington L, Makaranka S, Urquhart G, Vallet MV, Cartwright D, Marashi H, others. Enhancing clinical decision support with genomic tools in breast cancer: A Scottish perspective. The Breast. 2024;75:103728.
- Downie S, Chohan H, Ross L, McCann C, Hall P, Stillie A, Moran M, Sudlow C, Simpson AHR. New quality outcome indicators for bone metastases: expert consensus analysis of patients, their families and specialist healthcare professionals. BMJ Supportive & Palliative Care. 2024;14(e2):e2066–e2078.
- Bullen A, Ryan M, Ennis H, Gray E, Lorı́a-Rebolledo LE, McIntyre M, Hall P. Trade-offs between overall survival and side effects in the treatment of metastatic breast cancer: eliciting preferences of patients with primary and metastatic breast cancer using a discrete choice experiment. BMJ open. 2024;14(4):e076798.
- Lemmon E, Hanna C, Diernberger K, Paterson HM, Wild SH, Ennis H, Hall PS. Variation in colorectal cancer treatment and outcomes in Scotland: real world evidence from national linked administrative health data. International Journal of Population Data Science. 2024;9(1):2179.
2023
- Cafferkey J, Ferguson A, Grahamslaw J, Oatey K, Norrie J, Lone N, Walsh T, Horner D, Appelboam A, Hall P, others. Albumin versus balanced crystalloid for resuscitation in the treatment of sepsis: a protocol for a randomised controlled feasibility study,“ABC-Sepsis”. Journal of the Intensive Care Society. 2023;24(1):78–84.
- Mesa-Eguiagaray I, Dunlop H, Wild S, Bird SM, Williams L, Hall PS, Figueroa JD. Association of socioeconomic deprivation with breast cancer incidence, survival and ipsilateral recurrence by molecular subtype in Scotland, United Kingdom. AMER ASSOC CANCER RESEARCH 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA …. 2023;32(12).
- Diernberger K, Clausen E, Murray G, Wee B, Kaasa S, Hall P, Fallon M. Cancer pain assessment and management: does an institutional approach individualise and reduce cost of care?. BMJ supportive & palliative care. 2023;13(e3):e1258–e1264.
- Berdunov V, Millen S, Reynia S, Fryer N, Hall P, Perren T. Combined cost-utility analysis of the 21-gene assay to guide chemotherapy in HR+/HER2- breast cancer. Eur. J. Surg. Oncol. 2023;49(5):e236.
- Phillips I, Petrie R, Allan L, Hall P, Walton A, McMillan D, Peacock C, Primrose L, Vallet MV, Mencnarowksi J, others. Early prehabilitation in suspected locally advanced and metastatic lung cancer. BMJ Supportive & Palliative Care. 2023;13(e3):e908–e911.
- Dunlop HM, Williams LJ, Hall PS, Barber M, Dodds C, Figueroa JD. Evaluation of the association of area-level socioeconomic deprivation and breast cancer recurrence by oestrogen receptor subtypes in Scotland. Breast Cancer Res. 2023;25(1):106.
- Baxter MA, Spender LC, Walsh S, Bray S, Skinner G, King S, Hall PS, Seymour MJ, Petty RD, On Behalf Of The Go Investigators. Female sex but not oestrogen receptor expression predicts survival in advanced gastroesophageal adenocarcinoma-A post-hoc analysis of the GO2 trial. Cancers. 2023;15(9):2591–2591.
- Baxter MA, Spender LC, Walsh S, Bray S, Skinner G, King S, Hall PS, Seymour MJ, Petty RD, Investigators G. Female sex but not oestrogen receptor expression predicts survival in advanced gastroesophageal adenocarcinoma—A post-hoc analysis of the GO2 trial. Cancers. 2023;15(9):2591.
- Platt JR, Todd OM, Hall P, Craig Z, Quyn A, Seymour M, Braun M, Roodhart J, Punt C, Christou N, Taieb J, Karoui M, Brown J, Cairns DA, Morton D, Gilbert A, Seligmann JF. FOxTROT2: innovative trial design to evaluate the role of neoadjuvant chemotherapy for treating locally advanced colon cancer in older adults or those with frailty. ESMO Open. 2023;8(1):100642.
- Date K, Williams B, Cohen J, Chaudhuri N, Bajwah S, Pearson M, Higginson I, Norrie J, Keerie C, Tuck S, Hall P, Currow D, Fallon M, Johnson M. Modified-release morphine or placebo for chronic breathlessness: the MABEL trial protocol. ERJ Open Res. 2023;9(4):00167–2023.
- Henriksen PA, Hall P, MacPherson IR, Joshi SS, Singh T, Maclean M, Lewis S, Rodriguez A, Fletcher A, Everett RJ, Stavert H. Multicenter, prospective, randomized controlled trial of high-sensitivity cardiac troponin I–guided combination angiotensin receptor blockade and beta-blocker therapy to prevent anthracycline cardiotoxicity: the Cardiac CARE trial. Circulation. 2023;148(21):1680–1690.
- Goldstein DA, Ginsberg GM, Hofnung-Gabbay D, De Abreu Lourenco R, Loong HH, Goh BC, Chan KKW, Di Maio M, Perrone F, Hall PS, Zer A, Rosenbaum E. Multinational Analysis of Estimated Health Care Costs Related to Extended-Interval Fixed Dosing of Checkpoint Inhibitors. JAMA Netw Open. 2023;6(2):e230490.
- Hull MA, Ow PL, Ruddock S, Brend T, Smith AF, Marshall H, Song M, Chan AT, Garrett WS, Yilmaz O, others. Randomised, placebo-controlled, phase 3 trial of the effect of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid (EPA) on colorectal cancer recurrence and survival after surgery for resectable liver metastases: EPA for Metastasis Trial 2 (EMT2) study protocol. BMJ open. 2023;13(11):e077427.
- Stares M, Lewis G, Vallet M, Killean A, Tramonti G, Patrizio A, Mackean M, Harrow S, Barrie C, MacLennan K, Campbell S, Evans T, Tufail A, Edinburgh Cancer Informatics Programme, Hall P, Phillips I. Real-World Impact of SABR on Stage I Non-Small-Cell Lung Cancer Outcomes at a Scottish Cancer Centre. Cancers. 2023;15(5):1431–1431.
- Turner NC, Swift C, Jenkins B, Kilburn L, Coakley M, Beaney M, Fox L, Goddard K, Garcia-Murillas I, Proszek P, Hall P, others. Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate-and high-risk early-stage triple-negative breast cancer. Annals of Oncology. 2023;34(2):200–211.
- Purshouse K, Thomson JP, Vallet MV, Alexander L, Bonisteel I, Brennan M, Cameron DA, Figueroa JD, Furrie E, Haig P, Heck M, McCaughan H, Mitchell P, McVicars H, Primrose L, Silva I, Templeton K, Wilson N, Hall PS. The Scottish COVID cancer immunity prevalence study: A longitudinal study of SARS-CoV-2 immune response in patients receiving anti-cancer treatment. Oncologist. 2023;28(3):e145–e155.
- Lim HF, Sharma A, Gallagher C, Hall P. Value of ultrasound in assessing response to neoadjuvant chemotherapy in breast cancer. Clin. Radiol. 2023;78(12):912–918.
- Diernberger K, Luta X, Bowden J, Droney J, Lemmon E, Tramonti G, Shinkins B, Gray E, Marti J, Hall PS. Variation in hospital cost trajectories at the end of life by age, multimorbidity and cancer type. Int J Popul Data Sci. 2023;8(1):1768.
2022
- M F, K D, M L, Ps H, S A, R S, E V, D G, L G, R L, K M, Gd M, L N, C R, A ST, A C, S K, Laird BJA. An international open-label randomised trial comparing a two-step approach versus the standard three-step approach of the WHO analgesic ladder in patients with cancer. Ann. Oncol. 2022;33(12):1296–1303.
- Fallon M, Dierberger K, Leng M, Hall PS, Allende S, others. An international, open-label, randomised trial comparing a two-step approach versus the standard three-step approach of the WHO analgesic ladder in …. Annals of. 2022.
- Mesa-Eguiagaray I, Wild SH, Bird SM, Williams LJ, Brewster DH, Hall PS, Figueroa JD. Breast cancer incidence and survival in Scotland by socio-economic deprivation and tumour subtype. Breast Cancer Res. Treat. 2022;194(2):463–473.
- Hanna CR, Lemmon E, Hall PS, Ennis H, Morris E, McLoone P, others. Cancer trial impact: Understanding implementation of the short course oncology treatment (SCOT) trial findings in colorectal cancer at a national level. Clinical Oncology. 2022;34(9):554–560.
- Berdunov V, Millen S, Paramore A, Hall P, Perren T, Brown R, Griffin J, Reynia S, Fryer N, Longworth L. Cost-effectiveness analysis of the Oncotype DX Breast Recurrence Score test in node-positive early breast cancer. J. Med. Econ. 2022;25(1):591–604.
- Reid EA, Abathun E, Diribi J, Mamo Y, Wondemagegnhu T, Hall P, Fallon M, Grant L. Early palliative care in newly diagnosed cancer in Ethiopia: feasibility randomised controlled trial and cost analysis. BMJ Support. Palliat. Care. 2022;14(e1):e504–e507.
- Luta X, Diernberger K, Bowden J, Droney J, Hall P, Marti J. Intensity of care in cancer patients in the last year of life: a retrospective data linkage study. Br. J. Cancer. 2022;127(4):712–719.
- Hall PS, Peach J, Neilson AR. Practical application of outcomes based pricing models in Scotland: a feasibility project design. 2022.
- Henriksen PA, Hall P, Oikonomidou O, MacPherson IR, Maclean M, Lewis S, McVicars H, Broom A, Scott F, McKay P, Borley A, Rowntree C, Lord S, Collins G, Radford J, Guppy A, Payne JR, Newby DE, Mills NL, Lang NN. Rationale and Design of the Cardiac CARE Trial: A Randomized Trial of Troponin-Guided Neurohormonal Blockade for the Prevention of Anthracycline Cardiotoxicity. Circ. Heart Fail. 2022;15(7):e009445.
- Chitkara A, Mesa-Eguiagaray I, Wild SH, Hall PS, Cameron DA, Sims AH, Figueroa JD. Reproductive history differs by molecular subtypes of breast cancer among women aged ≤ 50 years in Scotland diagnosed 2009-2016: a cross-sectional study. Breast Cancer Res. Treat. 2022;196(2):379–387.
- Chitkara A, Mesa-Eguiagaray I, Wild SH, Hall PS, Cameron DA, Sims AH, Figueroa JD. Reproductive history differs by molecular subtypes of breast cancer among women aged ≤ 50 years in Scotland diagnosed 2009–2016: a cross-sectional study. Breast Cancer Research and Treatment. 2022;196(2):379–387.
- Chitkara A, Eguiagaray IM, Wild SH, Hall PS, Cameron DA, Sims AH, Figueroa JD. Reproductive history differs by molecular subtypes of breast cancer among women aged≤ 50 years in Scotland in 2009-16: A cross-sectional study. Breast Cancer Res. Treat. 2022.
- Yau C, Osdoit M, Noordaa MVD, Shad S, Wei J, Croze DD, Hamy AS, Laé M, Reyal F, Sonke GS, Steenbruggen TG, van Seijen M, Wesseling J, Martín M, Monte-Millán MD, López-Tarruella S, Consortium IST, Adamson K, Albain KS, Asare AL, et al. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol. 2022;23(1):149–160.
- Swann OV, Lone NI, Harrison EM, Tomlinson LA, Walker AJ, Seaborne MJ, Pollock L, Farrell J, Hall PS, Seth S, Williams TC, Preston J, Ainsworth JS, Semple FF, Baillie JK, Katikireddi SV, Akbari A, Lyons R, Simpson CR, Semple MG, et al. Studying the Long-term Impact of COVID-19 in Kids (SLICK). Healthcare use and costs in children and young people following community-acquired SARS-CoV-2 infection: protocol for an observational study using linked primary and secondary routinely collected healthcare data from England, Scotland and Wales. BMJ Open. 2022;12(11):e063271.
- Lemmon E, Connearn E, Hall P, Morris E, UK Colorectal Intelligence Hub And Yorkshire Cancer Research Bowel Cancer Improvement Programme Public-Patient Group. Successful public and patient involvement in bowel cancer research using linked administrative health data. Int. J. Popul. Data Sci. 2022;7(3).
- Anderson RA, Lambertini M, Hall PS, Wallace WH, Morrison DS, Kelsey TW. Survival after breast cancer in women with a subsequent live birth: Influence of age at diagnosis and interval to subsequent pregnancy. Eur. J. Cancer. 2022;173:113–122.
- Lemmon E, Rutherford A, Hall PS, Bell D, Henderson D, Downing A, Clark S. The use of social care services by individuals aged 50 and over diagnosed with colorectal cancer in Scotland: a linked data study. International Journal of Population Data Science. 2022;7(3).
2021
- Hall CC, Skipworth RJE, Blackwood H, Brown D, Cook J, Diernberger K, Dixon E, Gibson V, Graham C, Hall P, Haraldsdottir E, Hopkinson J, Lloyd A, Maddocks M, Norris L, Tuck S, Fallon MT, Laird BJA. A randomized, feasibility trial of an exercise and nutrition‐based rehabilitation programme (ENeRgy) in people with cancer. J. Cachexia Sarcopenia Muscle. 2021;12(6):2034–2044.
- Hanna CR, Lemmon E, Ennis H, Jones RJ, Hay J, Halliday R, Clark S, Morris E, Hall P. Creation of the first national linked colorectal cancer dataset in Scotland: prospects for future research and a reflection on lessons learned. Int J Popul Data Sci. 2021;6(1):1654.
- Downing A, Hall P, Birch R, Lemmon E, Affleck P, Rossington H, Boldison E, Ewart P, Morris EJA. Data Resource Profile: The COloRECTal cancer data repository (CORECT-R). International Journal of Epidemiology. 2021;50(5):1418-1418k.
- Salman RAS, Keerie C, Stephen J, Lewis S, Norrie J, Dennis MS, Newby DE, Wardlaw JM, Lip GYH, Parry-Jones A, White PM, Baigent C, Lasserson D, Oliver C, O'Mahony F, Amoils S, Bamford J, Armitage J, Emberson J, Rinkel GLJR, et al. Effects of oral anticoagulation for atrial fibrillation after spontaneous intracranial haemorrhage in the UK: a randomised, open-label, assessor-masked, pilot-phase, non-inferiority trial. Lancet Neurol. 2021;20(10):842–853.
- Hall PS, Swinson D, Cairns DA, Waters JS, Petty R, Allmark C, Ruddock S, Falk S, Wadsley J, Roy R, Tillett T, Nicoll J, Cummins S, Mano J, Grumett S, Stokes Z, Kamposioras KV, Chatterjee A, Garcia A, Waddell T, et al. Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer. JAMA Oncology. 2021;7(6):869–877.
- Luta X, Ottino B, Hall P, Bowden J, Wee B, Droney J, Riley J, Marti J. Evidence on the economic value of end-of-life and palliative care interventions: a narrative review of reviews. BMC Palliat. Care. 2021;20(1):89.
- Pearce J, Swinson D, Cairns D, Nair S, Baxter M, Petty R, Seymour M, Hall P, Velikova G, GO2 trial investigators. Frailty and treatment outcome in advanced gastro-oesophageal cancer: An exploratory analysis of the GO2 trial. J. Geriatr. Oncol. 2021;13(3):287–293.
- Aftimos P, Oliveira M, Irrthum A, Fumagalli D, Sotiriou C, Gal-Yam EN, Robson ME, Ndozeng J, Di Leo A, Ciruelos EM, de Azambuja E, Viale G, Scheepers ED, Curigliano G, Bliss JM, Reis-Filho JS, Colleoni M, Balic M, Cardoso F, Albanell J, et al. Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. Cancer Discov. 2021;11(11):2796–2811.
- Lemmon E, Hanna CR, Hall P, Morris EJA. Health economic studies of colorectal cancer and the contribution of administrative data: A systematic review. Eur. J. Cancer Care. 2021;30(5):e13477.
- Diernberger K, Luta X, Bowden J, Fallon M, Droney J, Lemmon E, Gray E, Marti J, Hall P. Healthcare use and costs in the last year of life: a national population data linkage study. BMJ Support. Palliat. Care. 2021;14(e1):bmjspcare–2020–002708.
- Newall AT, Beutels P, Tuffaha HW, Hall PS, Jit M. How can early stage economic evaluation help guide research for future vaccines?. Vaccine. 2021;40(2):175–177.
- Diernberger K, Shinkins B, Hall P, Kaasa S, Fallon M. Incompatible: end-of-life care and health economics. BMJ Support. Palliat. Care. 2021;11(3):296–298.
- Downie S, Cherry J, Hall P, Stillie A, Moran M, Sudlow C, Simpson AHRW. Metastatic bone disease: new quality performance indicator development. BMJ Support. Palliat. Care. 2021;14(e3):bmjspcare–2021–003025.
- Earl HM, Hiller L, Dunn J, Macpherson I, Rea D, Hughes-Davies L, McAdam K, Hall P, Mansi J, Wheatley D, Abraham JE, Caldas C, Gasson S, O'Riordan E, Wilcox M, Miles D, Cameron DA, Wardley A. Optimising the Duration of Adjuvant Trastuzumab in Early Breast Cancer in the UK. Clin. Oncol. 2021;33(1):15–19.
- McCabe C, Tramonti G, Sutton A, Hall P, Paulden M. Probabilistic One-Way Sensitivity Analysis with Multiple Comparators: The Conditional Net Benefit Frontier. Pharmacoeconomics. 2021;39(1):19–24.
- Baxter MA, Petty RD, Swinson D, Hall PS, O'Hanlon S. Real-world challenge for clinicians treating advanced gastroesophageal adenocarcinoma (Review). Int. J. Oncol. 2021;58(5):22.
- Maeda Y, Gray E, Figueroa JD, Hall PS, Weller D, Dunlop MG, Din FVN. Risk of missing colorectal cancer with a COVID-adapted diagnostic pathway using quantitative faecal immunochemical testing. BJS Open. 2021;5(4):zrab056–.
- Hulbert-Williams NJ, Leslie M, Hulbert-Williams L, Koczwara B, Watson EK, Hall PS, Ashley L, Coulson NS, Jackson R, Millington S, Group TFMWUKTS, Beatty L. The Finding My Way UK Clinical Trial: Adaptation Report and Protocol for a Replication Randomized Controlled Efficacy Trial of a Web-Based Psychological Program to Support Cancer Survivors. JMIR Res. Protoc. 2021;10(9):e31976.
- Baxter MA, Murphy J, Cameron D, Jordan J, Crearie C, Lilley C, Sadozye A, Maclean M, Hall P, Phillips A, Greger A, Madeleine J, Petty RD. The impact of COVID-19 on systemic anticancer treatment delivery in Scotland. Br. J. Cancer. 2021;124(8):1353–1356.
- Spencer K, Defourny N, Tunstall D, Cosgrove V, Kirkby K, Henry A, Lievens Y, Hall P. Variable and fixed costs in NHS radiotherapy; consequences for increasing hypo fractionation. Radiother. Oncol. 2021;166:180–188.
- Gray E, Figueroa JD, Oikonomidou O, MacPherson I, Urquhart G, Cameron DA, Hall PS. Variation in chemotherapy prescribing rates and mortality in early breast cancer over two decades: a national data linkage study. ESMO Open. 2021;6(6):100331.
2020
- Wardley AM, Ryder D, Misra V, Hall PS, Mackereth P, others. ACUFOCIN: Randomized clinical trial of ACUpuncture plus standard care versus standard care alone FOr Chemotherapy Induced peripheral Neuropathy (CIPN). ascopubs.org. 2020;38(15_suppl):12003–12003.
- Schmid P, Abraham J, Chan S, Wheatley D, Brunt AM, Nemsadze G, Baird RD, Park YH, Hall PS, Perren T, Stein RC, Mangel LS, Ferrero JM, Phillips M, Conibear J, Cortes J, Foxley A, de Bruin EC, McEwen R, Stetson D, et al. Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial. J. Clin. Oncol. 2020;38(5):423–433.
- Mesa-Eguiagaray I, Wild SH, Rosenberg PS, Bird SM, Brewster DH, Hall PS, Cameron DA, Morrison D, Figueroa JD. Distinct temporal trends in breast cancer incidence from 1997 to 2016 by molecular subtypes: a population-based study of Scottish cancer registry data. Br. J. Cancer. 2020;123(5):852–859.
- Figueroa JD, Brennan PM, Theodoratou E, Poon MTC, Purshouse K, Din FVN, Jin K, Mesa-Eguiagaray I, Dunlop MG, Hall PS, Cameron D, Wild SH, Sudlow CLM. Distinguishing between direct and indirect consequences of covid-19. BMJ. 2020;369:m2377.
- Tzolos E, Adamson PD, Hall PS, Macpherson IR, Oikonomidou O, MacLean M, Lewis SC, McVicars H, Newby DE, Mills NL, Lang NN, Henriksen PA. Dynamic Changes in High-Sensitivity Cardiac Troponin I in Response to Anthracycline-Based Chemotherapy. Clin. Oncol. 2020;32(5):292–297.
- Luta X, Diernberger K, Bowden J, Droney J, Howdon D, Schmidlin K, Rodwin V, Hall P, Marti J. Healthcare trajectories and costs in the last year of life: a retrospective primary care and hospital analysis. BMJ Support. Palliat. Care. 2020;14(e1):bmjspcare–2020–002630.
- McCabe C, Paulden M, Awotwe I, Sutton A, Hall P. One-Way Sensitivity Analysis for Probabilistic Cost-Effectiveness Analysis: Conditional Expected Incremental Net Benefit. Pharmacoeconomics. 2020;38(2):135–141.
- Reid E, Abathun E, Diribi J, Mamo Y, Hall P, Fallon M, Wondemagegnhu T, Grant L. Rationale and study design: A randomized controlled trial of early palliative care in newly diagnosed cancer patients in Addis Ababa, Ethiopia. Contemp Clin Trials Commun. 2020;18:100564.
- Earl H, Hiller L, Vallier AL, Loi S, McAdam K, Hughes-Davies L, Rea D, Howe D, Raynes K, Higgins HB, Wilcox M, Plummer C, Mahler-Araujo B, Provenzano E, Chhabra A, Gasson S, Balmer C, Abraham JE, Caldas C, Hall P, et al. Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT. Health Technol. Assess. 2020;24(40):1–190.
- Conefrey C, Donovan JL, Stein RC, Paramasivan S, Marshall A, Bartlett J, Cameron D, Campbell A, Dunn J, Earl H, Hall P, Harmer V, Hughes-Davies L, Macpherson I, Makris A, Morgan A, Pinder S, Poole C, Rea D, Rooshenas L, et al. Strategies to Improve Recruitment to a De-escalation Trial: A Mixed-Methods Study of the OPTIMA Prelim Trial in Early Breast Cancer. Clin. Oncol. 2020;32(6):382–389.
2019
- Earl HM, Hiller L, Vallier AL, Loi S, McAdam K, Hughes-Davies L, Harnett AN, Ah-See ML, Simcock R, Rea D, Raj S, Woodings P, Harries M, Howe D, Raynes K, Higgins HB, Wilcox M, Plummer C, Mansi J, Gounaris I, et al. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Lancet. 2019;393(10191):2599–2612.
- Gray E, Marti J, Wyatt JC, Brewster DH, Hall PS, SATURNE advisory group. Chemotherapy effectiveness in trial-underrepresented groups with early breast cancer: A retrospective cohort study. PLoS Med. 2019;16(12):e1003006.
- Gershon N, Berchenko Y, Hall PS, Goldstein DA. Cost effectiveness and affordability of trastuzumab in sub-Saharan Africa for early stage HER2-positive breast cancer. Cost Eff. Resour. Alloc. 2019;17(1):5.
- Abel L, Shinkins B, Smith A, Sutton AJ, Sagoo GS, Uchegbu I, Allen AJ, Graziadio S, Moloney E, Yang Y, Hall P. Early Economic Evaluation of Diagnostic Technologies: Experiences of the NIHR Diagnostic Evidence Co-operatives. Med. Decis. Making. 2019;39(7):857–866.
- Spencer K, Velikova G, Henry A, Westhoff P, Hall PT, van der Linden YM. Net Pain Relief After Palliative Radiation Therapy for Painful Bone Metastases: A Useful Measure to Reflect Response Duration? A Further Analysis of the Dutch Bone Metastasis Study. Int. J. Radiat. Oncol. Biol. Phys. 2019;105(3):559–566.
- Hall PS, Swinson D, Waters JS, Wadsley J, Falk S, others. Optimizing chemotherapy for frail and elderly patients (pts) with advanced gastroesophageal cancer (aGOAC): The GO2 phase III trial. ascopubs.org. 2019;37(15_suppl):4006–4006.
- Gray E, Marti J, Brewster DH, Wyatt JC, Piaget-Rossel R, Hall PS. Real-world evidence was feasible for estimating effectiveness of chemotherapy in breast cancer: a cohort study. Journal of Clinical Epidemiology. 2019;109:125-132.
- Rooshenas L, Scott LJ, Blazeby JM, Rogers CA, Tilling KM, Husbands S, Conefrey C, Mills N, Stein RC, Metcalfe C, Carr AJ, Beard DJ, Davis T, Paramasivan S, Jepson M, Avery K, Elliott D, Wilson C, Donovan JL, By-Band-Sleeve study group, et al. The QuinteT Recruitment Intervention supported five randomized trials to recruit to target: a mixed-methods evaluation. J. Clin. Epidemiol. 2019;106:108–120.
- Smith AF, Shinkins B, Hall PS, Hulme CT, Messenger MP. Toward a Framework for Outcome-Based Analytical Performance Specifications: A Methodology Review of Indirect Methods for Evaluating the Impact of Measurement Uncertainty on Clinical Outcomes. Clin. Chem. 2019;65(11):1363–1374.
2018
- Gray E, Marti J, Brewster DH, Wyatt JC, Hall PS. Independent validation of the PREDICT breast cancer prognosis prediction tool in 45,789 patients using Scottish Cancer Registry data. British Journal of Cancer. 2018;119(7):808-814.
2016
- Mehanna H, Wong WL, McConkey CC, Rahman JK, Robinson M, Hartley AGJ, Nutting C, Powell N, Al-Booz H, Robinson M, Junor E, Rizwanullah M, Von Zeidler SV, Wieshmann H, Hulme C, Smith AF, Hall P, Dunn J. PET-CT Surveillance versus Neck Dissection in Advanced Head and Neck Cancer. New England Journal of Medicine. 2016;374(15):1444-1454.
2013
- Cameron D, Brown J, Dent R, Jackisch C, Mackey J, Pivot X, Steger GG, Suter TM, Toi M, Parmar M, Laeufle R, Im YH, Romieu G, Harvey V, Lipatov O, Pienkowski T, Cottu P, Chan A, Im SA, Hall PS, et al. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol. 2013;14(10):933–942.
Last updated 2026-06-17.